Daiichi Sankyo Company, Limited (TYO:4568)
Japan · Delayed Price · Currency is JPY 3,999.00
-6.00 (-0.15%)
Oct 27, 2025, 3:30 PM JST
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 19,765 employees as of March 31, 2025. The number of employees increased by 1,039 or 5.55% compared to the previous year.
Employees
19,765
Change (1Y)
1,039
Growth (1Y)
5.55%
Revenue / Employee
97.38M JPY
Profits / Employee
14.97M JPY
Market Cap
7.41T
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 19,765 | 1,039 | 5.55% |
| Mar 31, 2024 | 18,726 | 1,291 | 7.40% |
| Mar 31, 2023 | 17,435 | 977 | 5.94% |
| Mar 31, 2022 | 16,458 | 425 | 2.65% |
| Mar 31, 2021 | 16,033 | 685 | 4.46% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,455 |
| HOYA Corporation | 37,909 |
| Otsuka Holdings | 35,338 |
| Olympus | 29,297 |
| M3, Inc. | 15,360 |
| Astellas Pharma | 13,643 |
| Eisai | 10,917 |
| Kyowa Kirin | 5,669 |
Daiichi Sankyo Company News
- 6 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions Transcript - Seeking Alpha
- 6 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions - Slideshow - Seeking Alpha
- 14 days ago - Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO - Business Wire
- 21 days ago - AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study - Seeking Alpha
- 21 days ago - DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02 - Benzinga
- 25 days ago - Daiichi Sankyo Establishes Third Research Institute in San Diego - Business Wire
- 26 days ago - Daiichi Sankyo Company, Limited (DSKYF) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Advances in FDA Review - GuruFocus